Effects of Preoperative Quadruple Therapy for Helicobacter pylori on Bariatric Surgery Metabolic Outcomes
Goday Arnó, Albert (Universitat Autònoma de Barcelona. Departament de Medicina)
Bagán, Andrea (Universitat Pompeu Fabra. Departament de Medicina i Ciències de la Vida)
Casajoana, Anna (Institut Hospital del Mar d'Investigacions Mèdiques)
Serra Saus, Carme (Hospital del Mar (Barcelona, Catalunya))
Pera Román, Manuel (Institut Hospital del Mar d'Investigacions Mèdiques)
Villatoro, Montserrat (Hospital del Mar (Barcelona, Catalunya))
Legido, Teresa (Institut Hospital del Mar d'Investigacions Mèdiques)
Julià, Helena (Xarxa Assistencial Universitària de Manresa)
Climent, Elisenda (Institut Hospital del Mar d'Investigacions Mèdiques)
Castañer, Olga (Hospital del Mar (Barcelona, Catalunya))
Flores Le Roux, Juana A. (Universitat Pompeu Fabra. Departament de Medicina i Ciències de la Vida)
Olano, Miguel (Hospital del Mar (Barcelona, Catalunya))
Pedro-Botet, Juan (Universitat Autònoma de Barcelona. Departament de Medicina)
Benaiges, David (Hospital del Mar (Barcelona, Catalunya))

Date:	2024
Abstract:	To assess the effects of Helicobacter pylori (HP) eradication with an omeprazole, clarithromycin, amoxicillin, and metronidazole (OCAM) regimen on the metabolic profile and weight loss 12 months after bariatric surgery (BS). Retrospective analysis of a prospective cohort of patients with morbid obesity undergoing BS. HP presence was tested preoperatively by gastric biopsy and treated with OCAM when positive. Short-term metabolic outcomes and weight loss were evaluated. HP infection was detected in 75 (45. 7%) of the 164 patients included. OCAM effectiveness was 90. 1%. HP-negative patients had a greater reduction in glucose levels at 3 (-14. 6 ± 27. 5 mg/dL HP-treated vs -22. 0 ± 37. 1 mg/dL HP-negative, p =0. 045) and 6 months (-13. 7 ± 29. 4 mg/dL HP-treated vs -26. 4 ± 42. 6 mg/dL HP-negative, p = 0. 021) and greater total weight loss (%TWL) at 6 (28. 7 ± 6. 7% HP-treated vs 30. 45 ± 6. 48% HP-negative, p = 0. 04) and 12 months (32. 21 ± 8. 11% HP-treated vs 35. 14 ± 8. 63% HP-negative, p = 0. 023). Preoperative treatment with OCAM has been associated to poorer glycemic and weight loss outcomes after BS. More research is needed on the influence of OCAM on gut microbiota, and in turn, the effect of the latter on metabolic and weight loss outcomes after BS.
Note:	Altres ajuts: Universitat Pompeu Fabra
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Helicobacter pylori ; Bariatric surgery ; Morbid obesity ; Gastric bypass ; Sleeve gastrectomy
Published in:	Obesity Surgery, Vol. 34 (february 2024) , p. 1196-1206, ISSN 1708-0428

DOI: 10.1007/s11695-024-07091-x
PMID: 38400943

11 p, 1.3 MB

The record appears in these collections:
Articles > Research articles
Articles > Published articles